2019 American Transplant Congress
Four-Year Follow Up of Kidney Transplantation Using Alemtuzumab Induction and Belatacept/Sirolimus Maintenance Therapy
1Surgery, Duke University, Durham, NC, 2Transplant Center, Emory University, Atlanta, GA
*Purpose: Kidney transplantation remains limited by the chronic toxicities associated with calcineurin inhibitors (CNIs) and steroids. The objective of this clinical trial was to determine…2019 American Transplant Congress
Impact of Once-Daily Tacrolimus on Trough Concentration Variability in Stable Adolescent and Young Adult Renal Transplant Recipients
Children's Hospital Colorado, Aurora, CO
*Purpose: High tacrolimus concentration variability (Vtac), likely influenced by medication non-adherence, is a risk factor for graft dysfunction and loss among renal transplant recipients (RTRs),…2019 American Transplant Congress
Lack of Response to Tocilizumab in Kidney Transplants with Chronic Antibody-Mediated Rejection
*Purpose: Chronic antibody mediated rejection (cAbMR) is a major cause of long-term kidney transplant (KT) loss. Traditional therapies for cAbMR have unclear efficacy with significant…2019 American Transplant Congress
Early Tacrolimus Trough Attainment in De Novo Kidney Transplant Recipients Treated with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac)
*Purpose: Early achievement of therapeutic tacrolimus concentrations has been associated with reduced rates of acute rejection. A prospective, randomized, controlled study demonstrated safe and efficacious…2019 American Transplant Congress
Difference in DSA Formation between Tacrolimus-XR and Tacrolimus-IR
*Purpose: Donor specific antibodies (DSA), whether pre-formed or developed de novo after kidney transplantation, have been associated with acute and chronic antibody mediated rejection, transplant…2019 American Transplant Congress
Outcomes of Reduced Thymoglobulin Induction Dosing in Elderly Kidney Transplant Recipients at a Steroid Sparing Center
Pharmacy, NewYork-Presbyterian, New York, NY
*Purpose: Studies have demonstrated a mortality benefit with kidney transplantation (KT) in elderly patients, but there is little consensus over optimal immunosuppression. Older KT recipients…2019 American Transplant Congress
Expansion of Myeloid Derived Suppressor Cells Following Alum Administration
Massachusetts General Hospital, Boston, MA
*Purpose: Immunosuppressive medications, such as calcineurin inhibitors, are critical to the survival of the transplant allograft but come with significant morbidity to the recipient and…2019 American Transplant Congress
Performance Improvement Initiative: Ambulatory Tool to Improve Tacrolimus Intrapatient Variability (IPV) Monitoring in Kidney & Liver Transplant Recipients
1University of Cincinnati, Cincinnati, OH, 2UC Health, Cincinnati, OH
*Purpose: High tacrolimus (TAC) intrapatient variability (IPV) is associated with poorer outcomes. Manual monitoring of TAC IPV is labor intensive and not always feasible. As…2019 American Transplant Congress
The Reduced Tacrolimus Metabolism Rate and Its Association with Estimated Glomerular Filtration Rate and Interstitial Fibrosis: A Study Using Korean Organ Transplantation Registry (KOTRY) Dataset
*Purpose: Tacrolimus is the key drug in clinical transplant, which has narrow therapeutic index. A few studies reported the association of tacrolimus metabolism rate with…2019 American Transplant Congress
Identification of Adult Liver Transplant Recipients Eligible to Participate in an Immunosuppression Withdrawal Trial Employing Non-Invasive Assessments of Allograft Status
*Purpose: Liver Immunosuppression Free Trial (LIFT) is a multicentre international prospective randomised controlled trial of biomarker-guided immunosuppression withdrawal in adult liver transplant recipients who meet…
- « Previous Page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- …
- 138
- Next Page »